The CDC predicts increased activity of Respiratory Syncytial Virus (RSV) for the upcoming winter season, urging clinicians to implement new prevention tools like nirsevimab and FDA-approved vaccines for vulnerable populations. The advisory comes as RSV activity shows a changing pattern, affecting infants, children, and adults, and causing thousands of hospitalizations annually.